CD4 and cancer: Tumor cell metastasis and drug resistance are impacted by epithelial–mesenchymal transition (EMT) (35, 36), and naïve CD4+ T-cell recruitment might inhibit TI Tregs, restore immune tumor killing, and inhibit cancer growth and metastases (37).